



Direttorat tat-Tabib Ewlieni tal-Gvern

Office of the Chief Medical Officer

DH CIRCULAR No. 482/2015
DH 3259/2015

8th October 2015

Attention All: Consultants
Medical Officers
Pharmacists
Pharmacy Technicians
Nurses

Re: Methylphenidate Hydrochloride 18mg and 36mg Prolonged Release Tablets

It is being brought to your attention that methylphenidate hydrochloride 18mg and 36mg prolonged release tablets are now available on the Government Formulary List for in-patient and out-patient use.

Methylphenidate hydrochloride prolonged release tablets are protocol regulated by protocol 126 (Annex I) and can be prescribed by Consultant Paediatrician (Community Paediatrics), Consultant Paediatrician (Paediatric Neurology and Neurodisability) and Consultant Psychiatrist.

For your attention please.

Dr. Denis Vella Baldacchino
Chief Medical Officer



Methylphenidate Hydrochloride 18mg and 36mg Prolonged Release Tablets

Prescriber Criteria: Consultant Paediatrician (Community Paediatrics)
Consultant Paediatrician (Paediatric Neurology and Neurodisability)
Consultant Psychiatrist

Out-patient and In-patient use:

1. Chronic Psychiatric Disorders Starting in Childhood

Treatment for Attention Deficit Hyperactivity Disorder in patients aged 6 years of age and over when remedial measures alone prove insufficient and where frequent dosing with methylphenidate immediate release is unsuccessful and not feasible. Should be reserved as a second line therapy, in exceptional circumstances, in cases where the supervising clinician has clear evidence that compliance with midday dosing is problematic.

Duration of Approval:

1 year